A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 144
第一作者单位:[1]Peking Univ, Hosp 1, Dept Infect Dis, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
Xu Jinghang,Yu Yanyan,Si Chongwen,et al.A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 144[J].HEPATOLOGY.2016,64:925A-925A.
APA:
Xu, Jinghang,Yu, Yanyan,Si, Chongwen,Zeng, Zheng,Li, Jun...&Xu, Zhongnan.(2016).A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 144.HEPATOLOGY,64,
MLA:
Xu, Jinghang,et al."A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 144".HEPATOLOGY 64.(2016):925A-925A